Target agents will be approved when ALL of the following are met (commercial and Medicaid have different step requirements):
Top-level: All conditions below must be met
Prior therapy requirement: Commercial: inadequate response, contraindication, or intolerance to at least a 3-month trial of TWO of: mepolizumab, dupilumab, tezepelumab, omalizumab. Medicaid: inadequate response, contraindication, or intolerance to at least a 3-month trial of TWO of: mepolizumab, dupilumab, omalizumab.
See policy: For Commercial Members Only (chunk 6) and For Medicaid Members Only (chunk 7).
Continuation eligible: The requested agent is eligible for continuation of therapy: member has been treated with the requested agent (starting on samples is not approvable) within the past 90 days; OR the prescriber states the member has been treated with the requested agent (starting on samples is not approvable) within the past 90 days AND is at risk if therapy is changed.
Agents Eligible for Continuation of Therapy (chunk 8).
Severe eosinophilic asthma diagnostic criteria: The member has a diagnosis of severe eosinophilic asthma and BOTH of the following: (1) diagnosis confirmed while on a high‑dose inhaled corticosteroid or daily oral corticosteroid by ONE of: baseline blood eosinophils >=150 cells/microliter OR FeNO >=20 ppb OR sputum eosinophils >=2%; AND (2) evidence of uncontrolled asthma demonstrated by ONE of: >=2 systemic steroid‑treated exacerbations in past 12 months; OR >=1 serious exacerbation requiring hospitalization/ventilation/ER/urgent care in past 12 months; OR controlled asthma that worsens with tapering corticosteroids; OR baseline (pre‑therapy) FEV1 <80% predicted.
Diagnostic thresholds and exacerbation criteria (chunk 8).
Indication and age support: If member has an FDA‑labeled indication, age must be within FDA labeling or there must be support for use in the member's age for the indication; compendia support is acceptable.
FDA labeling/compendia requirements (chunk 9).
Controller therapy and adherence: For severe eosinophilic asthma: member is NOT currently treated with another asthma biologic and has been on maximally tolerated inhaled corticosteroid for >=3 months with adherence for 90 days within the past 120 days; OR member currently treated with a biologic and is on an adequately dosed inhaled corticosteroid or maximally tolerated inhaled corticosteroid for >=3 months with adherence for 90 days within the past 120 days; OR member has intolerance/hypersensitivity or FDA contraindication to inhaled corticosteroids. PLUS member is currently treated for >=3 months and adherent for 90 days within the past 120 days with one of: LABA, LAMA, LTRA, or theophylline (or has intolerance/contraindication to these agents). The member will continue asthma control therapy in combination with the requested agent.
Controller therapy, duration, and adherence criteria (chunks 9-10).
Biologic and inhaled steroid rules: Either: member is NOT currently treated with another asthma biologic and meets the inhaled corticosteroid treatment/adherence criteria; OR member is currently treated with a biologic and meets inhaled corticosteroid treatment/adherence criteria or has intolerance/contraindication.
Biologic treatment options and ICS adherence (chunk 9).
Prescriber specialty: Prescriber is a specialist in the area of the member's diagnosis (e.g., allergist, immunologist, pulmonologist) or has consulted with such a specialist.
Prescriber specialty/consultation requirement (chunk 10).
Concomitant immunomodulators: Member will NOT be using the requested agent in combination with another immunomodulatory agent (e.g., TNF inhibitors, JAK inhibitors, IL‑4 inhibitors); OR if using in combination, BOTH: prescribing information for the requested agent does NOT limit use with another immunomodulatory agent; AND there is supportive evidence for combination therapy (submit clinical trials, phase III studies, or guidelines).
Concomitant therapy restrictions and evidence requirements (chunk 10).
Contraindications: Member does NOT have any FDA‑labeled contraindications to the requested agent.
Contraindications requirement (chunk 10).